Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

A Review of Clinical Studies of Stromal Vascular Fraction for the Treatment of Osteoarthritis with a Follow-up Period of Over Two Years.

Gao S., Zhao K., Lu Z.

Narrative Review on Osteoarthritis, Cartilage Damage, published in Stem Cell Rev Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Stem Cell Rev Rep (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40848103
DOI
10.1007/s12015-025-10965-x
Citations
1

Abstract (original English)

OA (Osteoarthritis), a degenerative joint disease, causes significant pain and functional impairment, with current treatments often falling short in achieving long-term efficacy. This review summarizes clinical studies evaluating the use of the SVF (stromal vascular fraction), a heterogeneous cell population derived from autologous adipose tissue, in OA treatment with follow-up of over two years. Clinical evaluations included imaging detection (X-ray, MRI) and evaluation, and functional scale scoring (VAS, WOMAC, KOOS). Most studies reported significant pain relieve and joint function improvements up to 2-5 years, with minimal adverse reactions. From the summary results of therapeutic effects, it can be seen that OA patient with younger age, lower BMI (body mass index), and less severe OA (K-L stage II-III) will achieve better clinical treatment effects. Patients with large cartilage defects or advanced stages (K-L stage IV) had limited benefits. Long-term efficacy plateaued after 2-3 years, highlighting the need for potential retreatment. Combined use with fibrin glue or PRP (platelet rich plasma) showed enhanced local retention and cartilage repair signals. Despite variability in preparation methods and evaluation scales, SVF emerges as a safe, autologous option to alleviate symptoms and delay joint replacement. Standardized protocols and larger, long-term follow-up trials ar

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansOsteoarthritisFollow-Up StudiesStromal Vascular FractionPlatelet-Rich PlasmaTreatment OutcomeAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research